{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:03:29Z","timestamp":1792440209609,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009664","name":"Sociedad Espa\u00f1ola de Cardiolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014384","name":"Amarin Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014384","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014389","name":"Amarin Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014389","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jacl.2025.04.193","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T15:54:36Z","timestamp":1744386876000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0000-7109","authenticated-orcid":false,"given":"Alberto","family":"Cordero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Gonzalez-Juanatey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Fernandez Olmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Fernandez-Freira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Bonanad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Alvarez-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1506-5555","authenticated-orcid":false,"given":"Armando","family":"Oterino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro J.","family":"Flores Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2025.04.193_bib0001","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1093\/eurheartj\/ehad446","article-title":"Eliminating atherosclerotic cardiovascular disease residual risk","volume":"44","author":"Makover","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.04.193_bib0002","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.recesp.2011.05.022","article-title":"Magnitude and characteristics of residual lipid risk in patients with a history of coronary revascularization: the ICP-bypass study","volume":"64","author":"Gonzalez-Juanatey","year":"2011","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.jacl.2025.04.193_bib0003","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/j.jacl.2024.07.001","article-title":"Addressing residual risk beyond statin therapy: new targets in the management of dyslipidaemias\u2013a report from the European Society of Cardiology Cardiovascular Round Table","volume":"18","author":"Mach","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.04.193_bib0004","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","article-title":"Triglycerides and residual atherosclerotic risk","volume":"77","author":"Raposeiras-Roubin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.04.193_bib0005","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurjpc\/zwad330","article-title":"Impact of hypertriglyceridaemia on cardiovascular mortality according to low-density lipoprotein cholesterol in a 15.6-million population","volume":"31","author":"Park","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.04.193_bib0006","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/eurjpc\/zwac286","article-title":"Remnant cholesterol in patients admitted for acute coronary syndromes","volume":"30","author":"Cordero","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.04.193_bib0007","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.04.193_bib0008","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C\u2013Lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2025.04.193_bib0009","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.04.193_bib0010","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.recesp.2013.01.012","article-title":"Clinical profile and prognosis of patients with low-density lipoprotein cholesterol <70mg\/dL and acute coronary syndrome","volume":"66","author":"Cordero","year":"2013","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.jacl.2025.04.193_bib0011","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.amjcard.2012.01.352","article-title":"Temporal patterns of lipid testing and statin therapy in acute coronary syndrome patients (from the Canadian GRACE Experience)","volume":"109","author":"Elbarouni","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2025.04.193_bib0012","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.jacc.2011.05.057","article-title":"Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol","volume":"58","author":"Lee","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2025.04.193_bib0013","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.amjcard.2010.06.009","article-title":"Low-density lipoprotein cholesterol level in patients with acute myocardial infarction having percutaneous coronary intervention (the cholesterol paradox)","volume":"106","author":"Cho","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2025.04.193_bib0014","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.recesp.2011.07.022","article-title":"Low levels of high-density lipoproteins cholesterol are independently associated with acute coronary heart disease in patients hospitalized for chest pain","volume":"65","author":"Cordero","year":"2012","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.jacl.2025.04.193_bib0015","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.3390\/ijms24065391","article-title":"HDL function and size in patients with on-target LDL plasma levels and a first-onset ACS","volume":"24","author":"Cordero","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacl.2025.04.193_bib0016","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2025.04.193_bib0017","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurheartj\/ehad889","article-title":"Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial","volume":"45","author":"Sayah","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.04.193_bib0018","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.04.193_bib0019","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.04.193_bib0020","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2025.04.193_bib0021","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.atherosclerosis.2015.07.035","article-title":"Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis","volume":"242","author":"Borow","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2025.04.193_bib0022","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jama.2021.0069","article-title":"New insights into plaque erosion as a mechanism of acute coronary syndromes","volume":"325","author":"Kolte","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2025.04.193_bib0023","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study","volume":"44","author":"Bj\u00f6rnson","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.04.193_bib0024","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/ATVBAHA.122.317163","article-title":"The remnant lipoprotein hypothesis of diabetes-associated cardiovascular disease","volume":"42","author":"Bornfeldt","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2025.04.193_bib0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jacl.2022.05.067","article-title":"Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: a review of key findings from REDUCE-IT","volume":"16","author":"Gaba","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2025.04.193_bib0026","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2021.08.031","article-title":"Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: an analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry","volume":"340","author":"Picard","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2025.04.193_bib0027","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.medj.2022.12.008","article-title":"Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease","volume":"4","author":"Krishnaraj","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.jacl.2025.04.193_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1220017","article-title":"Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention","volume":"10","author":"Toth","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacl.2025.04.193_bib0029","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/eurjpc\/zwad331","article-title":"The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis","volume":"31","author":"Kim","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2025.04.193_bib0030","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids versus corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2025.04.193_bib0031","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2025.04.193_bib0032","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/ehjci\/jead063","article-title":"Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT","volume":"24","author":"Rabbat","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacl.2025.04.193_bib0033","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.atherosclerosis.2020.10.006","article-title":"High levels of eicosapentaenoic acid are associated with lower pericoronary adipose tissue attenuation as measured by coronary CTA","volume":"316","author":"Bittner","year":"2021","journal-title":"Atherosclerosis"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425002673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425002673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T02:07:06Z","timestamp":1749607626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425002673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":33,"alternative-id":["S1933287425002673"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.04.193","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.04.193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}